Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The intervention probably leads to lower rebleeding (moderate certainty).
The intervention showed no clear difference in delayed cerebral ischemia (moderate certainty).
The intervention showed no clear difference in hydrocephalus (high certainty).
The review found no eligible studies for this question.
It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).
Comparison 6: SSRIs probably leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (moderate certainty).
Comparison 6: SSRIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
Comparison 7: TCAs may leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (low certainty).
Comparison 7: TCAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
Comparison 1: Alpha‐blockers showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
It is very uncertain whether comparison 2: Antipsychotics changes treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (very low certainty).
Comparison 2: Antipsychotics showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
The review found no eligible studies for this question.
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
Comparison 4: NaSSAs may leads to lower treatment efficacy ‐ Treatment response, as measured by the Global… compared with placebo (low certainty).
Comparison 4: NaSSAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.